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Abstract. Background: Our efforts, focused on the discovery of novel antiproliferative agents, 
led to the identification of an interesting oxadiazole derivative, MD77. Aim: To complete the 
studies concerning the antiproliferative profile of MD77 , we developed several new derivatives. 
Materials and Methods: The substitution pattern around the phenyl rings of this compound was 
analysed through the synthesis of positional isomers and of analogues bearing different substituents at 
the para positions (2-12). Results: The results of the antiproliferative activity of these derivatives versus 
HCT-116 and HeLa cancer cell lines shed light on the effects of the presence, nature and position of 
such substituents. Notably, derivative 4, a regioisomer of 1 in which the substituents at the para 
positions of the phenyl rings were inverted, showed the best antiproliferative profile, exhibiting a 
significant activity also against MCF7 and MDA-MB 468 cancer cell lines. Conclusion: Preliminary 
results showed the ability of compound 4 to counteract human recombinant topoisomerase II α 
relaxation activity. 
 




Cancer still ranks second behind cardiovascular diseases among the leading causes of death globally 
(1) and chemotherapy is the mainstay in the reduction of mortality. Nevertheless, anticancer drugs are 
generally extremely toxic, while their poor selectivity and the insurgence of resistance mechanisms 
clearly underscore the need of developing novel chemical entities, exhibiting higher efficacy and minor 
side effects. 
During our ongoing research concerning the identification of new compounds endowed with anticancer 
activity (2-11), we investigated the properties of 1,2,5-oxadiazole derivatives. Among them, MD77 (N-
[4-(4-chloro-phenyl)-1,2,5-oxadiazol-3-yl]-4-trifluoromethyl-benzamide 1, Figure 1) showed a good 
antiproliferative activity profile against a panel of 58 tumor cell lines derived from 9 cancer cell types 
(GI50 values ranging from 6.75×10-6 M against renal cancer cell TK10, to 5.46×10-7 M, leukemia, 
HL60TB), and showed Tumor Growth Inhibition (TGI) values lower than 1.00×10-4 M in most of the 
cancer cell lines (3). Therefore, with the aim to integrate the previously obtained data (2), we decided 
to investigate the effects of phenyl ring substitutions on the antiproliferative activity, by designing 
(Figure 1) and synthesizing (Figure 2) several compounds related to 1 (2-12), to complete our library 
(2). Some compounds showed on the phenyl rings the same substituents of 1 but at different positions, 
while others were substituted with a trifluoromethyl group or with a chlorine atom. 
All compounds were tested against HCT116 and HeLa cell lines. Since isomer 4 showed the 
most interesting growth inhibition results, we also explored its effect on the cellular viability of breast 
cancer cells (MCF-7 and MDA-MB 468), and the outcomes confirmed the encouraging trend of activity. 
We also investigated its mechanism of action using as probes its derivatives 20 (Figure 3), bearing 
fluorescent moieties, and observing their behavior into the cells. Finally, preliminary studies were 
performed to explore its potential molecular targets. 
 
Materials and Methods 
Chemistry. Reagents and solvents were all purchased from Sigma-Aldrich (Saint Louis, MO, USA), 
except for Oregon Green 488 carboxylic acid succinimide ester obtained from Thermo Fisher Scientific 
(Waltham, MA, USA), and were used without further purification. Anhydrous solvents were used 
without further drying. Reactions, performed in conventional conditions or by a microwave synthesizer 
(Biotage® Initiator; Biotage, Upsala, Sweden) were monitored by thin-layer chromatography on 
aluminum-backed Silica Gel 60 plates (70-230 mesh; Merck, Darmstadt, Germany), using an ultraviolet 
fluorescent lamp at 254 nm and 365 nm. Visualization was supported by opportune staining reagents. 
Purification of intermediates and final compounds was performed via flash column chromatography on 
Geduran Si 60 (40-63 μm, Merck). All the tested compounds were characterized by means of 1H and 
13C NMR spectra on a Varian Oxford 300 MHz instrument (Palo Alto, CA, USA), equipped with a non-
reverse probe at 25°C, operating at 300 MHz for 1H, 75 MHz for 13C and 282 MHz for 19F. Chemical 
shifts are expressed as δ (ppm) from tetramethylsilane resonance in the indicated solvent (TMS: δ=0.0 
ppm). The coupling constants (J-values) are expressed in Hertz (Hz). All spectroscopic data match the 
assigned structures. Melting points were determined in open capillary tubes on a Buchi Melting Point 
B-540 (Buchi, Flawil, Switzerland). Mass spectrometry analyses were carried out on an LTQ Orbitrap 
XL mass spectrometer (Thermo Fisher Scientific) equipped with a Finnigan IonMax Electrospray 
interface. The purity of the compounds was checked by HPLC analysis (≥95%). 
The synthesis of 4-bromo and 4-methyl benzoyl chlorides was performed following the 
procedure reported in literature (2). 
Synthesis of 1,2,5-oxadiazol-3-amines 17a-g. The amines 17a-g were obtained as previously described 
(Figure 2) (3). The characterization of the new key intermediates 17b and 17f is reported below. 
4-(4-methylphenyl)-1,2,5-oxadiazol-3-amine (17b). Starting compound: 4-methylbenzaldehyde (1.2 
mmol). Yield: 8% as white solid (m.p.: 126.7-128.5°C). 1H-NMR (CDCl3): δ 2.38 (s, 3H, CH3), 4.26 
(br s, 2H, NH2 exchanged with D2O), 7.36 (d, J = 8.2 Hz, 2H, ArH), 7.64 (d, J = 8.2 Hz, 2H, ArH) ppm. 
13C-NMR (CDCl3): δ 21.44, 122.58, 127.44, 130.09, 140.87, 146.92, 154.31 ppm. ESI-MS: calcd. for 
C9H9N3O 175, found 176 [M+H]+. 
4-(4-bromophenyl)-1,2,5-oxadiazol-3-amine (17f). Starting compound: 4-bromobenzaldehyde (2.70 
mmol). Yield: 18% as light brown solid (m.p.: 143.8-144.8°C). 1H-NMR (CDCl3): δ 4.20 (br s, 2H, 
NH2 exchanged with D2O), 7.62 (d, J = 8.3 Hz, 2H, ArH), 7.68 (d, J = 8.3 Hz, 2H, ArH) ppm. 13C-NMR 
(CDCl3): δ 125.02, 125.89, 129.38, 135.68, 146.70, 154.56 ppm. ESI-MS: calcd. for C8H6BrN3O 240, 
found 241 [M+H]+. 
Synthesis of 1,2,5-oxadiazol-3-amides 1-12 and 18. Compounds 1-4, 7-9 and 12 were obtained as 
previously reported (2), while the new derivatives 5, 6, 10,11 and 18 were synthesized using the 
following the procedures. 
Synthesis of 4-bromo-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (5). 4-Bromobenzoyl 
chloride (0.306 mmol) was added to a solution of 17c (0.255 mmol) and 4-dimethylaminopyridine 
(0.306 mmol) in dry 1,2-dichloroethane (1.5 ml), at room temperature, under nitrogen atmosphere. The 
reaction mixture was irradiated in a microwave synthesizer at 120°C and 300 W for 45 min. The solution 
was treated with water (1.5 ml) and extracted with dichloromethane (3 × 1 ml). The collected organic 
phases were washed with 1N HCl, dried over Na2SO4, filtered and evaporated under reduced pressure 
to give a residue, which was purified by flash column chromatography (eluent mixture: 
cyclohexane/ethyl acetate, 80:20). 
Yield: 11% as brown solid (m.p.: 195.5-197.0°C). 1H-NMR (CDCl3): δ 7.47 (d, J=8.1 Hz, 2H, 
ArH), 7.65 (d, J=8.7 Hz, 2H, ArH), 7.68 (d, J=8.7 Hz, 2H, ArH), 7.76 (d, J=8.1 Hz, 2H, ArH), 8.18 (br 
s, 1H, NH exchanged with D2O) ppm. 13C-NMR (CDCl3): δ 123.78, 127.46, 129.16, 129.25, 129.56, 
131.80, 133.18, 135.03, 147.18, 153.76, 166.48 ppm. ESI-MS: calcd. for C15H9BrClN3O2 378, found 
377 [M-H]-. 
General procedure for the synthesis of amides 6, 10, 11 and 18. To a suspension of NaH 60% dispersion 
in mineral oil (0.3 mmol) in dry N-N-dimethylformamide (3 ml) cooled on an ice bath under nitrogen 
atmosphere, the appropriate 4-substuituted phenyl-1,2,5-oxadiazol-3-amine (0.25 mmol) was added, 
and the mixture was stirred at 0°C for 20 min. Subsequently, the suitable acyl chloride (0.3 mmol) was 
added dropwise at 0°C and the mixture was stirred at 60°C for 12 h. After the addition of water (3 ml), 
N-N-dimethylformamide was removed under reduced pressure and the obtained residue was extracted 
with ethyl acetate (3× 2 ml). The organic phase was dried over Na2SO4 and evaporated under vacuum 
to obtain the crude product, which was purified by flash column chromatography (eluent mixture: 
cyclohexane/ethyl acetate, 80:20). 
4-methyl-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (6). Starting compounds: 17c and 4-
methylbenzoyl chloride. Yield: 24% as brown solid (m.p.: 163.5-164.0°C). 1H-NMR (CDCl3): δ 2.37 
(s, 3H, CH3), 7.25 (d, J=8.4 Hz, 2H, ArH), 7.38 (d, J=8.4 Hz, 2H, ArH), 7.58 (d, J=8.6 Hz, 2H, ArH), 
7.70 (d, J=8.6 Hz, 2H, ArH), 8.07 (br s, 1H, NH exchanged with D2O) ppm. 13C-NMR (CDCl3): δ 21.91, 
124.31, 127.89, 129.06, 129.17, 129.79, 130.06, 137.27, 144.59, 149.13, 149.75, 165.50 ppm. ESI-MS: 
calcd. for C16H12ClN3O2 313, found 312 [M-H]-. 
4-trifluoromethyl-N-(4-(4-bromophenyl)-1,2,5-oxadiazol-3-yl)benzamide (10). Starting compounds: 
17f and 4-trifluoromethylbenzoyl chloride. Yield: 20% as off-white solid (m.p.: 242.5-244.8°C). 1H-
NMR (CDCl3): δ 7.57 (d, J=8.7 Hz, 2H, ArH), 7.64 (d, J=8.7 Hz, 2H, ArH), 7.81 (d, J=8.2 Hz, 2H, 
ArH), 8.00 (d, J=8.2 Hz, 2H, ArH), 8.15 (br s, 1H, NH exchanged with D2O) ppm. 13C-NMR (CDCl3): 
δ 121.50, 122.76, 125.12, 126.33, 129.22, 129.25, 133.18, 135.19, 135.42, 135.63, 151.41, 170.08 ppm. 
19F-NMR (CD3OD): δ -63.63 (s, CF3) ppm. ESI-MS: calcd. for C16H9BrF3N3O2 412, found 411 [M-H]-
. 
4-trifluoromethyl-N-(4-(4-methylphenyl)-1,2,5-oxadiazol-3-yl)benzamide (11). Starting compounds: 
17b and 4-trifluoromethylbenzoyl chloride. Yield: 19% as gray solid (m.p.: 118.8-121.5°C). 1H-NMR 
(CDCl3): δ 2.44 (s, 3H, CH3), 7.36 (d, J=8.2 Hz, 2H, ArH), 7.57 (d, J=8.2 Hz, 2H, ArH), 7.79 (d, J=8.6 
Hz, 2H, ArH), 7.98 (d, J=8.6 Hz, 2H, ArH), 8.12 (br s, 1H, NH exchanged with D2O) ppm. 13C-NMR 
(CDCl3): δ 31.15, 122.31, 125.69, 125.78, 126.45 (q), 126.25, 127.69, 127.89, 128.32, 130.29, 130.45, 
134.31, 141.66, 148.57, 150.20, 165.78 ppm. 19F-NMR (CD3OD): δ -63.75 (s, CF3) ppm. ESI-MS: 
calcd. for C17H12F3N3O2 347, found 346 [M-H]-. 
4-chloro-2-nitro-N-(4-(4-(trifluoromethyl)phenyl)-1,2,5-oxadiazol-3-yl)benzamide (18). Starting 
compounds: 17g and 4-chloro-2-nitrobenzoyl chloride. Yield: 52% as yellowish solid (m.p.: 208-
209°C). 1H-NMR (CD3OD): δ 7.77 (d, J=8.2 Hz, 1H, ArH), 7.86 (d, J=5.3 Hz, 2H, ArH), 7.90 (d, J=2.0 
Hz, 1H, ArH), 8.00 (d, J=8.4 Hz, 2H, ArH), 8.22 (d, J=2.0 Hz, 1H, ArH) ppm. 13C-NMR (CD3OD): δ 
118.60-122.18-125.67-129.40 (q), 123.02, 125.96-126.02-126.08-126.16 (q), 127.59, 129.98, 130.42, 
130.99, 131.54, 132.78-133.21-133.67-134.05 (q), 133.52, 146.98, 147.37, 153.30, 165.07 ppm. 19F-
NMR (CD3OD): -63.04 ppm. ESI-MS: calcd. for C16H8ClF3N4O4 412, found 411 [M-H]-. 
Synthesis of 2-amino-4-chloro-N-(4-(4-(trifluoromethyl)phenyl)-1,2,5-oxadiazol-3-yl)benzamide (19) 
To a solution of benzamide 18 (0.242 mmol) in ethyl acetate (15.61 ml), SnCl2 (1.212 mmol) was added 
and the mixture was refluxed for 3 h. A saturated aqueous solution of NaHCO3 was added until pH 7-8 
and the precipitated tin salts were filtered. The aqueous phase was extracted with ethyl acetate (3 × 3 
ml). The collected organic layers were dried over Na2SO4, filtered and evaporated under vacuum. The 
obtained residue was purified by flash column chromatography (eluent mixture: cyclohexane/AcOEt, 
8:2) to afford intermediate 19.  
Yield: 79% as white solid (m.p.: 155-156°C). 1H-NMR (CD3OD): δ 6.63 (dd, J=8.6, 2.1 Hz, 
1H, ArH), 6.78 (d, J=2.1 Hz, 1H, ArH), 7.71 (d, J=8.6 Hz, 1H, ArH), 7.79 (d, J=8.4 Hz, 1H, ArH), 7.94 
(d, J=8.4 Hz, 1H, ArH) ppm. 13C-NMR (CD3OD): δ 115.02, 115.49, 117.50, 118.57-122.16-125.70-
129.30 (q), 125.96-126.04-126.11-126.16 (q), 127.60, 130.01, 130.47, 132.78-133.24-133.68-134.10 
(q), 138.07, 146.40, 150.25, 153.31,165.59 ppm.19F-NMR (CD3OD): δ -63.07 ppm. ESI-MS: calcd. for 
C16H10ClF3N4O2 382, found 383 [M+H]+. 
Synthesis of N-{5-chloro-2-[4-(4-trifluoromethyl-phenyl)-1,2,5-oxadiazol-3-ylcarbamoyl]-phenyl}-2-
(6-hydroxy-3-oxo-3H-xanthen-9-yl)-terephthalamic acid and N-{5-chloro-2-[4-(4-trifluoromethyl-
phenyl)-1,2,5-oxadiazol-3-ylcarbamoyl]-phenyl}-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-iso 
phthalamic acid  mixture (20). Oregon Green 488 carboxylic acid succinimide ester (0.078 mmol) was 
added to a solution of amine 19 (0.078 mmol) and N-N-diisopropylethylamine (0.39 mmol) in dry N-
N-dimethylformamide (12 ml), and the mixture was stirred for 5 h at room temperature (12). After the 
removal of dimethylformamide under vacuum, the residue was initially filtered on silica and then 
purified by flash column chromatography (eluent mixture: dichloromethane/methanol, 90:10) providing 
the mixture 20. Yield: 23% as yellow oil. ESI-MS: calcd. for C37H20ClF3N4O8 741, found 763 [M+Na]+. 
 
Antiproliferative assay on HCT-116 cell line. 
Cell line culture. The human colorectal cancer cell line HCT-116 (Cell-Lab Unimore, University of 
Modena and Reggio Emilia, Italy) was cultured in Dulbecco's modified Eagle medium (DMEM; 
Euroclone, Devon, UK), supplemented with 10% heat-inactivated fetal bovine serum (Euroclone) and 
1% Pen/Strep (Euroclone). Cultures were equilibrated with humidified 5% carbon dioxide in air at 
37°C. All studies were performed in Mycoplasma-negative cells, as routinely determined with the 
MycoAlert Mycoplasma detection kit (Lonza, Walkersville, MD, USA) (2). 
Cytotoxicity screening. The cytotoxicity of the compounds was determined by MTT assay (13,14). 
Briefly, the cells were seeded into 96-well plates and cultured overnight. Various concentrations of the 
test compounds dissolved in DMSO were then added and incubated for 48 h. After incubation, 10% v/v 
of a solution of 0.5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; 
Sigma-Aldrich) was added and then incubated at 37°C for 3 h. The medium was removed and 100 μl 
DMSO were added to dissolve the dark blue crystals. After incubation for 30 min at room temperature 
to ensure the dissolution of all crystals, absorbance was measured using an ELISA plate reader 
(TECAN, Männedorf, Switzerland) at 595 nm (2). 
 Antiproliferative assay on HeLa cell line  
Cell line culture. The human cervix adenocarcinoma cell line HeLa was grown in Nutrient Mixture F-
12 [HAM] (Sigma Chemical Co., St. Louis, MO USA) supplemented with 10% Heat-inactivated fetal 
calf serum (FCS; Invitrogen, Carlsbad, CA, USA), 100 U/ml penicillin, 100 µg/ml streptomycin and 
0.25 µg/ml amphotericin B (Sigma Chemical Co., St. Louis, MO USA). The cells were cultured at 
37°C in a moist atmosphere of 5% carbon dioxide in air (11). 
Cytotoxicity screening. HeLa (4-5 × 104) cells were seeded into a 24-well cell culture plate. After 
incubation for 24 h, various concentrations of the test agents were added, and the cells were further 
incubated in standard conditions for 48 h. A trypan blue assay (15) was performed to determine 
cell viability. Cytotoxicity data were expressed as GI50 values, i.e. the concentration of the 
test agent inducing a 50% reduction in the cell count, compared to control cultures (11). 
Cellular viability of MCF-7 and MDA-MB 468 cell lines. 
Cell line culture. Two breast cancer cell lines were used, namely MCF-7 (ATCC: HTB-22) and MDA-
MB 468 (ATCC: HTB-132). Both cell lines were cultured in DMEM supplemented with 10% FCS and 
1% GlutaMAX (BioConcept, Allschwil, Switzerland). Cells were kept at 37°C in a humidified 
atmosphere supplemented with 5% carbon dioxide. 
Cell viability. Cell viability was determined through the assessment of the metabolic activity. Briefly, 
MCF-7 (ATCC: HTB-22) or MDA-MB 468 (ATCC: HTB-132) cells were seeded at a density of 5,000 
cells/well in 96-well plates (Eppendorf, Schönenbuch, Switzerland). Compound 4 was solubilized in 
DMSO at a final concentration of 15 mM and stored at 4˚C until further use. One day after the seeding, 
the cells were exposed to a medium containing a serial dilution of compound 4. After a 48-h incubation, 
cell viability was determined using the resazurin viability fluorometric cell viability kit (PromoCell 
GmbH, Heidelberg, Germany) according to the manufacturer’s instruction. Fluorescence was detected 
using the TECAN Infinite M200Pro plate reader (Ex=530 nm, Em=590 nm). Viability was calculated 
as fold of solvent control, after subtracting the fluorescence of the medium. Data were plotted using 
Graph Pad Prism (version 6.07, La Jolla, CA, USA); the inhibitory potency was estimated calculating 
the GI50 value using a nonlinear fit regression. 
MeT-5A inhibition growth assay. MeT-5A (human mesothelium) cells were grown in RPMI-1640 
(Sigma Chemical Co.), supplemented with 2.4 g/l Hepes, 0.11 g/l Na-pyruvate, 2.5 g/l glucose, 2g/l Na-
bicarbonate. Heat-inactivated FCS 10%, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml 
amphotericin B (Sigma Chemical Co.) were added to the medium. The cells were cultured at 37 °C in 
a moist atmosphere of 5% carbon dioxide in air. Cells (3×104) were seeded into a 24-well cell culture 
plate. After incubation for 24 h, various concentrations of the test agents were added to the complete 
medium and the cells were further incubated for 48 h. A trypan blue assay was performed to determine 
the cell viability. Cytotoxicity data were expressed as GI50 values, i.e., the concentration of the test 
agent inducing 50% reduction in the number of cancer cells, compared to control cultures. 
Microscope fluorescence analysis. The breast cancer cell line MCF-7 (ATCC HBT-22) was used for 
the assessment of microtubule interaction with the fluorescent mixture 20. MCF-7 cells were cultured 
in supplemented DMEM on glass cover slips until the 70% confluence was reached. Then, the 
fluorescent mixture 20 was added to the cell culture at a concentration of 1, 10, and 100 µM and 
incubated for 24 h at 37°C, 5% carbon dioxide in humidified atmosphere. 
Fluorescence microscopy. Fluorescence microscopy was performed using an inverted fluorescent 
microscope Leica DM IL LED (Heerbrugg, Switzerland). Briefly, MCF-7 cells were fixed in 
paraformaldehyde 4% for 15 min at room temperature. After three washes in phosphate buffer saline 
(PBS) at pH 7.4, cells were stained first with phalloidin 555 (Thermo Fischer, Zug, Switzerland) for 20 
min and then with Hoechst 33342 (Thermo Fisher) for 10 min. All cells were co-stained with phalloidin 
555 (staining F-actin of the cytoskeleton) and Hoechst 33342 (staining DNA). Three final washes were 
then performed before mounting the glass slides, and then fluorescent microscopy was performed. 
Images were taken using the software Leica suite X (LASX), and they were analyzed using the Image 
Processing Software. 
Topoisomerase-mediated DNA relaxation assay. Supercoiled pBR322 plasmid DNA (0.25 µg; 
Fermentas Life Sciences, Burlington, Ontario, Canada) was incubated with 1 U topoisomerase II 
(human recombinant topoisomerase II α; USB Corporation, Cleveland, OH, USA) and the test 
compounds as indicated, for 60 min at 37°C in 20 µl reaction buffer. Reactions were stopped 
by adding 4 µl stop buffer (5% sodium dodecyl sulfate (SDS), 0.125% bromophenol blue, and 
25% glycerol), 50 µg/ml proteinase K (Sigma-Aldrich) and were further incubated for 30 min 
at 37°C. The samples were separated by electrophoresis on a 1% agarose gel at room 
temperature. The gels were stained with ethidium bromide 1 µg /ml in TAE buffer (0.04 M 
Tris-acetate and 0.001 M EDTA) and transilluminated by UV light; fluorescence emission was 
visualized by a CCD camera, coupled to a Bio-Rad Gel Doc XR apparatus (11). 
Statistical analysis. For statistical analysis, the software GraphPad Prim was used. For statistical 
analysis of the cell viability the One-way ANOVA with Dunett’s multi comparison test was used. The 
two-way ANOVA was applied for statistical analysis of the cell counting, while two data points 
comparing the GI50-values was analyzed using an unpaired t-test. A p-value <0.05 was considered 
statistically significant. 
 
Results and Discussion 
Chemistry. Our library of 1,2,5-oxadiazole derivatives, including the previously reported products 1-4, 
7-9, 12, was integrated with the new analogues 5, 6, 10, 11, obtained following the synthetic pathway 
described in the literature, and depicted in  Figure 2 (2). Compound 20 was afforded as a mixture of 
regioisomers, as described in Figure 3. 
The suitable commercially available benzaldehydes were treated with hydroxylamine to give 
oximes 13a-g, which were then converted into the corresponding chloro-oximes 14a-g in the presence 
of N-chlorosuccinimide. The chlorine atom was substituted with a cyano group by treatment with 
potassium cyanide (15a-g). Intermediates 15a-g were reacted in the presence of hydroxylamine to 
afford the corresponding amino-bis-oximes (acetamidines) 16a-g that were cyclized in basic condition 
to the amines 17a-g (16). The latter were coupled with the suitable benzoyl chlorides in the presence of 
sodium hydride to afford the products 1-12 and the amide 18 (Figure 2) (2). Finally, the nitro group of 
intermediate 18 was reduced by treatment with tin chloride to afford the amine 19, which was coupled 
with Oregon  
Antiproliferative activity on HCT-116 and HeLa cell lines. To complete our previous set of data (2), 
compounds 5, 6, 10 and 11 were tested on HCT-116 cell line (human colorectal cancer); then, to widen 
the antiproliferative profile of this class, all the derivatives were also assayed on HeLa cells (human 
cervix adenocarcinoma). The results are reported in Table I.  
The new compounds exhibited a lower antiproliferative activity against HCT-116 cell line in 
comparison with the previously synthesized derivatives (11); similarly, the GI50 values on HeLa cells 
were generally higher with respect to the majority of those obtained for the previous candidates. Among 
this set, compound 4 showed the highest activity versus HeLa cell line, confirming its promising 
antiproliferative effect, previously observed on HCT-116 cells (GI50=1.48 μM). Therefore, it was also 
tested against the breast cancer cell lines MCF-7 and MDA-MB 468. 
Cellular viability of MCF-7 and MDA-MB 468 cell lines. The effect of compound 4 on the viability of 
MCF7 and MDA-MB 468 cells was assessed by measuring their metabolic activity, through the 
resazurin fluorometric cell viability kit. The results of the test are reported in Figure 4. 
The assay revealed a significant inhibition of metabolic activity upon treatment with compound 
4, resulting in a reduction of resazurin to resafurin. In both cell lines, compound 4 exhibited a 
comparable potency with an GI50 of 8.50 μM in MCF-7 and an GI50 of 10.59 μM in MDA-MB 468 cells 
(Student’s t-test, p>0.05, Figure 4).  
Antiproliferative activity on MeT-5A. Compound 4, endowed with the highest antiproliferative activity, 
and compound 1, as reference, were tested on MeT-5A cell line, showing GI50 values of 7.3 μM and 9.3 
μM respectively, after 48 h of incubation. The compounds exhibited a lower cytotoxicity against healthy 
cells with respect to the tested cancer cell lines, suggesting a certain degree of specificity. 
Fluorescent microscopy analysis. Following the incubation of MCF-7 breast cancer cells with the 
fluorescent mixture 20, a lower viability was observed compared to the control group, in which no 
compound was added. Three different concentrations (1, 10 and 100 µM) of the compound were used, 
but only the highest gave a relevant fluorescent signal (Figure 5). 
The fluorescence microscopy analysis suggested an overlay between the actin and the 
fluorescent derivative of compound 4 (mixture 20), without showing substantial alterations of the 
cellular shape. Therefore, the affinity of the molecule towards the actin filament indicates a potential 
interaction may occur. 
AlphaScreen-based assay. Several literature works have reported that oxadiazole-based derivatives can 
inhibit the signal transducer and activator of transcription 3 (STAT3) transcription factor, by binding to 
its SH2 domain (10, 17–19). Therefore, the potential inhibitory activity of the most interesting 
compounds (1,2 and 4) was tested at 30 µM concentration by an AlphaScreen-based assay, though 
without positive results (data not shown). 
Topoisomerase-mediated DNA relaxation assays. Some oxadiazole derivatives have also been reported 
to have inhibitory activity on topoisomerases (20, 21), so the same three compounds, endowed with the 
highest antiproliferative activity (1,2 and 4), were tested against topoisomerase II (Table II).  
All the tested compounds showed an interesting inhibitory effect on topoisomerase II relaxation 
activity: the results of the assay revealed a complete enzyme inhibition at a concentration of 100 μM. 
Conclusions 
To gain new insights into the effect of phenyl substitution on the antiproliferative properties of the 
previously reported compound 1, a small set of oxadiazoles was synthesized and tested on different 
human tumor cell lines. Among the synthesized derivatives, compounds 2 and 4 showed the most 
interesting antiproliferative activity, highlighting that only slight modifications on compound 1, such 
as the shift of the CF3 group to the meta position (2) or the inversion of the position of the substituents 
(4), are well tolerated. Interestingly, the antiproliferative effect of 4 on non-tumorigenic MeT-5A cells 
appeared lower with respect to that exerted on tumor cells, suggesting a certain specificity. Further 
preliminary studies suggested that the antiproliferative properties of this compound could be related to 
the interaction with microtubules and to the ability to inhibit the relaxation activity of topoisomerase II. 
Therefore, these results confirm that compound 4 could be considered as a promising antiproliferative 
agent, endowed with a good specificity for the tested cancer cell lines. 
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 Figure 1  
 
Compound R R1 Compound R R1 
1 p-Cl p-CF3 7 p-Cl H 
 2 p-Cl m-CF3 8 m-Cl p-CF3 
3 p-Cl o-CF3 9 o-Cl p-CF3 
4 p-CF3 p-Cl 10 p-Br p-CF3 
5 p-Cl p-Br 11 p-CH3 p-CF3 
6 p-Cl p-CH3 12 H p-CF3 
 
  




 Figure 3 
 
  
Table I. Antiproliferative activity of compounds 1-12 against the human colorectal cancer (HCT-116) 
and cervix adenocarcinoma (HeLa) cell lines, evaluated after 48 hours of exposure to the compounds 
(2, 11).  
 










1 p-Cl p-CF3 1.3±0.2 3.6±0.4 7 p-Cl H n.a. 54.5±12.7 
2 p-Cl m-CF3 7.4±1.15 4.1±0.8 8 m-Cl p-CF3 15.4±2.8 5.7±1.1 
3 p-Cl o-CF3 n.a. 74.5±10.2 9 o-Cl p-CF3 56.7±3.1 19.2±2.3 
4 p-CF3 p-Cl 0.95±0.02 1.48±0.3 10 p-Br p-CF3 47.7±6.3 29.2±4.2 
5 p-Cl p-Br 85.6±16 18.6±3.5 11 p-CH3 p-CF3 56.5±9.1 36.0±5.4  
6 p-Cl p-CH3 47.2±5.4 23.2±1.8 12 H p-CF3 n.a. 27.0±0.4 
GI50 values (µM) are means±SD of at least three separate experiments; n.a.: not active (≥100).  
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Figure 4. Effect of compound 4 on the viability of breast cancer cells (at the top); specifically, on the 
ER-positive MCF-7 (A) and the ER-negative MDA-MB 468 (B) cell lines. The viability of cells exposed 
to serial dilutions of compound 4 for 48 h was assessed by quantifying the enzymatic reduction of 
resazurin. The experiments (n=4) were conducted in triplicates. Data are presented as mean ± SD. * 
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Figure 5. Images showing the presence of the fluorescent compound 20 in 488 MCF-7 breast cancer 
cells. Phalloidin Alexa Fluor 555 dye staining (A); Hoechst 3342 staining (B); Fluorescent mixture 20 
staining (C). 
 
Table II. Effect of compounds 1,2 and 4 on the relaxation of supercoiled plasmid DNA by 
topoisomerase II (TopoII). 
 
Compound R R1 
Topo II inhibitory 
effect (100 µM) 
1 p-Cl p-CF3 +++ 
2 p-Cl m-CF3 +++ 
4 p-CF3 p-Cl +++ 
+++ complete inhibition; ++- partial inhibition, +-- weak inhibition, --- no inhibition 
 
